Literature DB >> 26290284

Molecular mechanisms of fatty liver in obesity.

Lixia Gan1, Wei Xiang, Bin Xie, Liqing Yu.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of liver disorders ranging from simple steatosis to advanced pathologies, including nonalcoholic steatohepatitis and cirrhosis. NAFLD significantly contributes to morbidity and mortality in developed societies. Insulin resistance associated with central obesity is the major cause of hepatic steatosis, which is characterized by excessive accumulation of triglyceride-rich lipid droplets in the liver. Accumulating evidence supports that dysregulation of adipose lipolysis and liver de novo lipogenesis (DNL) plays a key role in driving hepatic steatosis. In this work, we reviewed the molecular mechanisms responsible for enhanced adipose lipolysis and increased hepatic DNL that lead to hepatic lipid accumulation in the context of obesity. Delineation of these mechanisms holds promise for developing novel avenues against NAFLD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26290284     DOI: 10.1007/s11684-015-0410-2

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  152 in total

1.  Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C.

Authors:  Elena Lima-Cabello; María Victoria García-Mediavilla; María E Miquilena-Colina; Javier Vargas-Castrillón; Tamara Lozano-Rodríguez; Miguel Fernández-Bermejo; José Luis Olcoz; Javier González-Gallego; Carmelo García-Monzón; Sonia Sánchez-Campos
Journal:  Clin Sci (Lond)       Date:  2011-03       Impact factor: 6.124

2.  Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.

Authors:  María Eugenia Miquilena-Colina; Elena Lima-Cabello; Sonia Sánchez-Campos; María Victoria García-Mediavilla; Miguel Fernández-Bermejo; Tamara Lozano-Rodríguez; Javier Vargas-Castrillón; Xabier Buqué; Begoña Ochoa; Patricia Aspichueta; Javier González-Gallego; Carmelo García-Monzón
Journal:  Gut       Date:  2011-01-26       Impact factor: 23.059

Review 3.  Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome.

Authors:  Paul D Berk
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

4.  Gene expression in human NAFLD.

Authors:  Dario Greco; Anna Kotronen; Jukka Westerbacka; Oscar Puig; Perttu Arkkila; Tuula Kiviluoto; Saara Laitinen; Maria Kolak; Rachel M Fisher; Anders Hamsten; Petri Auvinen; Hannele Yki-Järvinen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-04-03       Impact factor: 4.052

5.  Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice.

Authors:  Emil D Bartels; Morten Lauritsen; Lars B Nielsen
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

6.  Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis.

Authors:  Jiang Wei Wu; Shu Pei Wang; Fernando Alvarez; Stéphanie Casavant; Nicolas Gauthier; Lynda Abed; Krishnakant G Soni; Gongshe Yang; Grant A Mitchell
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

7.  Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome.

Authors:  Achim Lass; Robert Zimmermann; Guenter Haemmerle; Monika Riederer; Gabriele Schoiswohl; Martina Schweiger; Petra Kienesberger; Juliane G Strauss; Gregor Gorkiewicz; Rudolf Zechner
Journal:  Cell Metab       Date:  2006-05       Impact factor: 27.287

8.  Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis.

Authors:  Jie Zhou; Maria Febbraio; Taira Wada; Yonggong Zhai; Ramalinga Kuruba; Jinhan He; Jung Hoon Lee; Shaheen Khadem; Songrong Ren; Song Li; Roy L Silverstein; Wen Xie
Journal:  Gastroenterology       Date:  2007-11-28       Impact factor: 22.682

9.  Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis.

Authors:  Robert K Semple; Alison Sleigh; Peter R Murgatroyd; Claire A Adams; Les Bluck; Sarah Jackson; Alessandra Vottero; Dipak Kanabar; Valentine Charlton-Menys; Paul Durrington; Maria A Soos; T Adrian Carpenter; David J Lomas; Elaine K Cochran; Phillip Gorden; Stephen O'Rahilly; David B Savage
Journal:  J Clin Invest       Date:  2009-01-26       Impact factor: 14.808

10.  The g0/g1 switch gene 2 is an important regulator of hepatic triglyceride metabolism.

Authors:  Yinfang Wang; Yahui Zhang; Hang Qian; Juan Lu; Zhifeng Zhang; Xinwen Min; Mingjian Lang; Handong Yang; Nanping Wang; Peng Zhang
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

View more
  11 in total

1.  Detection and Quantification of Lipid Droplets in Differentiated Human Podocytes.

Authors:  Shamroop Kumar Mallela; Devang Maheshkumar Patel; Gloria Michelle Ducasa; Sandra Merscher; Alessia Fornoni; Hassan Al-Ali
Journal:  Methods Mol Biol       Date:  2019

2.  Influence of different concentrations of uric acid on oxidative stress in steatosis hepatocytes.

Authors:  Shi Cheng; Yan Yang; Yong Zhou; Wei Xiang; Hua Yao; Ling Ma
Journal:  Exp Ther Med       Date:  2018-02-12       Impact factor: 2.447

Review 3.  The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease.

Authors:  Grace Park; Sunhee Jung; Kathryn E Wellen; Cholsoon Jang
Journal:  Exp Mol Med       Date:  2021-05-20       Impact factor: 8.718

Review 4.  Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease.

Authors:  Sabina Paglialunga; Clayton A Dehn
Journal:  Lipids Health Dis       Date:  2016-09-17       Impact factor: 3.876

5.  Absence of Tissue Inhibitor of Metalloproteinase-4 (TIMP4) ameliorates high fat diet-induced obesity in mice due to defective lipid absorption.

Authors:  Siva S V P Sakamuri; Russell Watts; Abhijit Takawale; Xiuhua Wang; Samuel Hernandez-Anzaldo; Wesam Bahitham; Carlos Fernandez-Patron; Richard Lehner; Zamaneh Kassiri
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

6.  Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.

Authors:  Yasushi Honda; Takaomi Kessoku; Yuji Ogawa; Wataru Tomeno; Kento Imajo; Koji Fujita; Masato Yoneda; Toshiaki Takizawa; Satoru Saito; Yoji Nagashima; Atsushi Nakajima
Journal:  Sci Rep       Date:  2017-02-14       Impact factor: 4.379

7.  Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

Authors:  Irena Ciećko-Michalska; Małgorzata Szczepanek; Iga Wierzbicka-Tutka; Janina Zahradnik-Bilska; Tomasz Mach
Journal:  Arch Med Sci Atheroscler Dis       Date:  2018-12-28

8.  NF- κ B/HDAC1/SREBP1c pathway mediates the inflammation signal in progression of hepatic steatosis.

Authors:  Yunwei Guo; Xiaoying Zhang; Zhiyun Zhao; Hongyun Lu; Bilun Ke; Xin Ye; Bin Wu; Jianping Ye
Journal:  Acta Pharm Sin B       Date:  2020-02-21       Impact factor: 11.413

9.  Involvement of Reactive Oxygen Species in the Hepatorenal Toxicity of Actinomycin V In Vitro and In Vivo.

Authors:  Fu-Juan Jia; Zhuo Han; Jia-Hui Ma; Shi-Qing Jiang; Xing-Ming Zhao; Hang Ruan; Wei-Dong Xie; Xia Li
Journal:  Mar Drugs       Date:  2020-08-15       Impact factor: 5.118

10.  Compounds that modulate AMPK activity and hepatic steatosis impact the biosynthesis of microRNAs required to maintain lipid homeostasis in hepatocytes.

Authors:  Jèssica Latorre; Francisco J Ortega; Laura Liñares-Pose; José M Moreno-Navarrete; Aina Lluch; Ferran Comas; Núria Oliveras-Cañellas; Wifredo Ricart; Marcus Höring; You Zhou; Gerhard Liebisch; P A Nidhina Haridas; Vesa M Olkkonen; Miguel López; José M Fernández-Real
Journal:  EBioMedicine       Date:  2020-03-03       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.